http://www.businessw...amp;newsLang=en. arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency's(EMEA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending the companyâ€™s product candidate ARG201 (native type 1 bovine collagen) for the treatment of diffuse systemic sclerosis, also known as systemic scleroderma (SSc) for designation as an orphan medicinal product to the European Commission. arGentis Pharmaceuticals. 01/06/09. (See also: Scleroderma Treatments)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
arGentis Receives Favorable Opinion in Europe
No replies to this topic